Gammagard Liquid Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Reported Case Report of Recovery from Rabies Using Intrathecal Rabies Immune Globulin was Flawed - ADDENDUM
Can J Neurol Sci. 2024 Apr 4:1. doi: 10.1017/cjn.2024.39. Online ahead of print.NO ABSTRACTPMID:38572615 | DOI:10.1017/cjn.2024.39 (Source: The Canadian Journal of Neurological Sciences)
Source: The Canadian Journal of Neurological Sciences - April 4, 2024 Category: Neurology Authors: Alan C Jackson Charles E Rupprecht Reeta S Mani Nidia Ar échiga-Ceballos Darryn L Knobel Source Type: research

Immune-globulin
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research

Efficacy of CMV Immunoglobulin as Cytomegalovirus Prophylaxis in High Risk Lung Transplant Recipients
Purpose: Cytomegalovirus (CMV) infection remains an important cause of morbidity and mortality after lung transplantation, particularly in high-risk subjects and is associated with chronic lung allograft dysfunction (CLAD). Chemoprophylaxis with valganciclovir (VAL) is routinely employed. Addition of cytomegalovirus specific immune globulin (CMVIG) may offer additional protection. We compared the incidence of CMV infection following VAL prophylaxis plus CMVIG compared with VAL alone in high-risk recipients. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , R. Girgis, C.K. Lawson, H. Hassouna Source Type: research

Adjunctive Cytogam and CMV Insight T-Cell Immunity Assay for Refractory CMV Disease in Heart Transplant Recipients - Single-Center Case Series of Challenging Cases
Introduction: Refractory CMV disease portends a poor prognosis after orthotopic heart transplant (OHT). Genotyping CMV to detect antiviral resistance mutations in UL97 and UL54 genes is recommended. There are off-label antiviral drugs and adjunctive therapies used for treatment of resistant CMV, but with limited evidence. Here we describe our experience with the adjunctive use of Cytomegalovirus Immune Globulin Intravenous [Human] (CytoGam) with antiviral drugs in 2 high-risk D+/R- CMV mismatch patients with refractory CMV disease (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , R. Gottlieb, C. Spak Source Type: research

Does the Number of Donor Specific Antibodies Crossed at the Time of Heart Transplant Impact Post-Transplant Outcome?
Purpose: Most heart transplant programs do not cross donor-specific antibodies (DSA) at the time of transplant due to risk of hyperacute rejection or delayed hyperacute rejection as well as increased risk of antibody-mediated rejection (AMR) in the first year after heart transplant. Other programs have been crossing DSA if they are at low level (less than 5000 MFI). Post-transplant therapy such as anti-thymocyte globulin and intravenous immune globulin have been reported to be helpful to prevent AMR. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: J. Kobashigawa, M. Kittleson, E. Kransdorf, , G. Jamero, A. Kanungo, M. Lee, N. Bhatnagar, L. Stern, A. Nikolova, L. Czer, F. Esmailian, J. Patel Source Type: research

Guideline No. 448: Prevention of Rh D Alloimmunization
J Obstet Gynaecol Can. 2024 Mar 27:102449. doi: 10.1016/j.jogc.2024.102449. Online ahead of print.ABSTRACTOBJECTIVE: This guideline provides recommendations for the prevention of Rh D alloimmunization (isoimmunization) in pregnancy, including parental testing, routine postpartum and antepartum prophylaxis, and other clinical indications for prophylaxis. Prevention of red cell alloimmunization in pregnancy with atypical antigens (other than the D antigen), for which immunoprophylaxis is not currently available, is not addressed in this guideline.TARGET POPULATION: All Rh D-negative pregnant individuals at risk for Rh D allo...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - March 29, 2024 Category: OBGYN Authors: Karen Fung-Kee-Fung Karen Wong Jennifer Walsh Candyce Hamel Gwen Clarke Source Type: research

Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research